Skip to content
OpenCapital
Get started

Rogers Corporation ROG EV / EBITDA

EV / EBITDA at other companies

3M logo
3MMMM
13.7×-0.3×
Biogen logo
BiogenBIIB
11.2×+2.8×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
14×-8.7×
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
14.6×+2.1×
Entegris logo
EntegrisENTG
24.9×+6.4×
Chemours logo
ChemoursCC
23.6×+13.8×

Other financials

Income statement

See full
Revenue$200.5M+5.2%
Gross profit$64.6M+13.3%
Operating income$10.7M+3,667%
Net income$4.5M+421%
EPS (diluted)$0.25+413%

Balance sheet

See full
Cash & equivalents$195.8M+11.5%
Total debt$29.8M-10.5%
Total equity$1.2B-6.1%
Total assets$1.4B-5.6%

Cash flow

See full
Operating cash flow$5.8M-50.4%
CapEx$4.7M-51.0%
Free cash flow$1.1M-47.6%

Valuation

See full
Market cap$2.89B+53.1%

Profitability

See full
Gross margin32.2%-0.7pp
Operating margin8.1%-6.7pp
Net margin-7.4%-9.5pp
FCF margin8.5%+1.8pp

Returns & leverage

See full
Return on equity-4.9%-6.3pp
Debt / equity0×0.0×
Current ratio4×+0.1×

Where this comes from

Calculated from Rogers Corporation’s reported figures.

enterprise value/ebitda=1,889.1×

Based on the most recent quarter.

The official record: Rogers Corporation’s 10-Q, filed October 30, 2025, on SEC EDGAR. View the filing →

Ask your AI about Rogers Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rogers Corporation's EV / EBITDA?
Rogers Corporation (ROG) reported EV / EBITDA of 1,889.1× in Q3 2025.
How has Rogers Corporation's EV / EBITDA changed year-over-year?
Rogers Corporation's EV / EBITDA increased by 10923.3% year-over-year, from 17.1× to 1,889.1×.
What is the long-term trend for Rogers Corporation's EV / EBITDA?
Over 4 years (2020 to 2024), Rogers Corporation's EV / EBITDA has grown at a 0.5% compound annual growth rate (CAGR), from 19.8× to 20.3×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.